Lexington’s Shire HGT looks to develop therapy for rare eye disorder in infants

Shire HGT, of Lexington, will seek to help develop a therapy to treat a rare eye disorder in infants, thanks to an acquisition by its Irish parent company.

The Irish drug company Shire PLC said Tuesday that it has acquired a Swedish company with promising therapy for the disorder. The Swedish company, Premacure AB, is developing a protein replacement therapy to prevent retinopathy of prematurity, or ROP, a potentially blinding disorder that primarily affects premature infants. It is one of the most common causes of vision loss in childhood.


Shire operates its Human Genetic Therapies division, known as Shire HGT, from Lexington. About a year ago, it reported having nearly 1,400 full-time employees in Massachusetts.

In a press release, the company said the acquisition will allow Shire HGT to enter a new therapeutic area, neonatology, while maintaining its focus on developing novel therapies for the treatment of rare diseases.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of